Residual Cardiovascular Risk

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

Genetic risk models and variant tools help to guide intensive interventions for high-risk carriers and personalized management for others.

A low-energy total diet replacement program before colorectal cancer surgery helped patients lose weight safely, improved certain symptoms, and showed cost-effectiveness.